Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bank of Nova Scotia — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.01 (market cap $39.89B), while Bank of Nova Scotia trades at $87.59 (market cap $107.21B). The key difference: Bank of Nova Scotia is far larger — about 2.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Bank of Nova Scotia pays a 3.67% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | BNS | |
|---|---|---|
Market Cap | $39.89B | $107.21B |
Sector | Health | Financials |
52-Week High | $491.22 | $87.59 |
52-Week Low | $278.09 | $54.50 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BNS trades at $87.59, up 1.78% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $1.47, exceeding expectations, and maintains a net income margin of 24.86%. Recent news highlights dividend strength and the acquisition of MapleMark Bank to bolster growth. Analyst consensus is 53% buy, with a P/E of 17.15 indicating reasonable valuation.
Outlook is positive due to consistent earnings performance and strategic acquisitions, but risks include high debt levels and economic sensitivity. The stock offers income appeal with a $1.14 dividend, yet investors should monitor credit provisions amid soft economic conditions noted in Q2 2026 reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
